---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-24-000007"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T03:53:29.809962+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexaria's DehydraTECH semaglutide outperforms Rybelsus in human pilot study

## Summary
- DehydraTECH semaglutide showed 43% higher peak blood levels vs Rybelsus; levels higher at all 19 time points.
- Blood glucose reduced by 5.01% at 24 hours vs baseline for DehydraTECH; Rybelsus group unchanged.
- No moderate nausea or diarrhea reported with DehydraTECH; Rybelsus caused both side effects.
- Lexaria preparing additional human and animal studies on expedited basis for GLP-1 drugs.

## SEC filing metadata
- accession: 0001640334-24-000007
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033424000007/0001640334-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033424000007/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-24-000007
- JSON: https://secwatch.observer/filing/0001640334-24-000007.json
- Plain text: https://secwatch.observer/filing/0001640334-24-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.